منابع مشابه
The immuno-oncology framework
Developers of cancer immunotherapy have struggled for decades to achieve clinical success in using the patient's immune system to treat cancer. In the absence of a defined development paradigm for immunotherapies, conventional criteria established for chemotherapy were applied to these agents. This article summarizes the recent lessons for development of agents in the immunotherapy space, descr...
متن کاملMevalonate Metabolism in Immuno-Oncology
Immuno-oncology not only refers to the multifaceted relationship between our immune system and a developing cancer but also includes therapeutic approaches that harness the body's immune system to fight cancer. The recognition that metabolic reprogramming governs immunity was a key finding with important implications for immuno-oncology. In this review, we want to explore how activation and dif...
متن کاملStatistical issues and challenges in immuno-oncology
BACKGROUND The development of immuno-oncologic agents poses unique challenges, namely that both efficacy and safety profiles differ from previously characterized cytotoxic and pathway-specific agents. In addition, exponential distribution is usually assumed in study designs with time-to-event endpoints such as overall survival or progression-free survival. This assumption might lead to wrong es...
متن کاملPrimer on immuno-oncology and immune response.
Advances in the understanding of the immunogenicity of tumors have provided the basis for immuno-oncology, the development of immunotherapeutic agents that augment the patient's antitumor immunity and disrupt the immune-regulatory circuits that allow tumors to evade the immune system. Two immunomodulatory agents recently have been introduced for the treatment of malignancy: sipuleucel-T and ipi...
متن کاملPre-Clinical Murine Models: Syngeneic Models for Immuno-Oncology
Experimental animal models are crucial in the study of the pathological development of cancer and evaluation of the efficacy of novel therapeutic or preventive agents. To date, several newer targeted therapeutics have been unsuccessful. Novel therapeutics that have often appeared to perform well in preclinical models have failed in the clinic. Many factors contribute to these failures, but the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Surgery
سال: 2019
ISSN: 0007-1323,1365-2168
DOI: 10.1002/bjs.11224